Acetylcholine Receptor Antibodies and Striated Muscle Antibody Reflexive Panels, and Titin Antibody
Ordering Recommendation
Acceptable reflexive panel for diagnosing myasthenia gravis. Panel contains binding, blocking, and modulating antibodies; titin antibody; and SMA IgG screen with titer.
Quantitative Radioimmunoassay/Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Semi-Quantitative Indirect Fluorescent Antibody/Semi-Quantitative Flow Cytometry
1-8 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
Plain red top or Serum Separator Tube (SST).  
Specimen Preparation
Transport 1.5 mL serum. (Min. 0.7 mL) Separate serum from cells ASAP or within one hour of collection. Transfer to an ARUP Standard Transport Tube.  
Storage/Transport Temperature
Refrigerated. Frozen is also acceptable.   
Unacceptable Conditions
Plasma. Hemolyzed, lipemic, moderately icteric serum or contaminated specimens.  
Repeated freeze-thaw cycles should be avoided.  
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year  
Reference Interval
Test Number Components Reference Interval
0080009 Acetylcholine Receptor Binding Antibody Negative: 0.0-​0.4 nmol/L
Positive:  0.5 nmol/L or greater
0099580 Acetylcholine Receptor Blocking Antibody Effective November 18, 2013
Negative:0-​26% blocking
Indeterminate: 27-​41% blocking
Positive: 42% or greater blocking
0099521 Acetylcholine Receptor Modulating Antibody Negative: 0-​45% modulating
Positive: 46% or greater modulating
2005636 Titin Antibody Negative:  0.00 to 0.45 IV
Indeterminate:  0.46 to 0.71 IV
Positive:  0.72 IV or greater
 Striated Muscle Antibody IgG Screen Less than 1:40 No antibody detected
 Striated Muscle Antibody, IgG Titer Less than 1:40 No antibody detected
Interpretive Data
In early-onset myasthenia gravis patients with anti-acetylcholine receptor antibodies, the presence of titin antibody indicates a 95-100 percent likelihood of an underlying thymoma.

See Compliance Statement B:
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
If Acetylcholine Receptor Binding Antibody result is greater than 0.4 nmol/L or Acetylcholine Receptor Blocking Antibody result is greater than 26 percent, then Acetylcholine Receptor Modulating Antibody will be added. If Striated Muscle Ab is greater than or equal to 1:40, then a titer will be added. Additional charges apply.
CPT Code(s)
83516; 83519, 83516; if reflexed, add 83516, 86255; if reflexed, add 86256
Component Test Code*Component Chart Name
0050747Striated Muscle Antibody, IgG Screen
0050748Striated Muscle Antibody, IgG Titer
0080009Acetylcholine Binding Antibody
0099580Acetylcholine Blocking Antibody
2005637Titin Antibody
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • AChR Binding Antibody
  • AChR Antibody
  • Anti-Skeletal Muscle IgG Antibodies
  • Anti-Striated Antibody
  • anti-tintin Ab
  • Muscle (Skeletal) Antibodies
  • Muscle nicotinic Acetylcholine Receptor
  • Myasthenia Gravis Antibodies
  • Myoid Antibody
  • Skeletal Muscle Antibodies
  • Striational Antibodies